Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes

Atherosclerosis

Volumn 163, Issue 1, 2002, Pages 59-68

  Gratl, Victoria ^a   Cheung, Raphael C ^b   Chen, Biao ^a   Taghibiglou, Changiz ^a   Van Iderstine, Stephen C ^a   Adeli, Khosrow ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF WINDSOR   (Canada)

Author keywords

High density lipoproteins; Microsomal triglyceride transfer protein; Simvastatin

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN; STATIN; TRANSFERRIN; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL CULTURE; CELL SECRETION; CELL TYPE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DENSITY; DOSE CALCULATION; DRUG EFFECT; DRUG POTENCY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; INCUBATION TIME; LIPOGENESIS; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TIME; ANIMAL; ANIMAL MODEL; BIOSYNTHESIS; COMPARATIVE STUDY; DOSE RESPONSE; HAMSTER; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; REFERENCE VALUE; SECRETION; SENSITIVITY AND SPECIFICITY;

ANIMAL; APOLIPOPROTEIN A-I; BASE SEQUENCE; CELLS, CULTURED; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; HAMSTERS; HEPATOCYTES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; REFERENCE VALUES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SIMVASTATIN; SUPPORT, NON-U.S. GOV'T; ANIMALS; CRICETINAE;

EID: 0036015984     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00754-7     Document Type: Article

References (38)

1. Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease
2. HDL and coronary artery disease
3. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations
4. Role of high density lipoproteins in the regression of atherosclerosis
5. The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis
6. Apolipoprotein A-I metabolism in subjects with a PstI restriction fragment length polymorphism of the apoA-I gene and familial hypoalphalipoproteinemia
7. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
8. Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation
9. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
11. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
12. Lipoprotein physiology
13. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells
14. Role of cholesterol ester mass in regulation of secretion of apoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship
15. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs
16. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig
17. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
18. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
19. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
20. Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro
21. Bile acid synthesis in hamster hepatocytes in primary culture: Sources of cholesterol and comparison with other species
22. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model
23. Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes
24. Secretion of apolipoprotein B in serum-free cultures of human hepatoma cell line HepG2
25. Precautionary measures for collecting blood destined for lipoprotein isolation
26. A solution hybridization/RNase protection assay with riboprobes to determine absolute levels of apoB, A-I, and E mRNA in human hepatoma cell lines
27. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
28. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs
29. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin
30. Human S mu binding protein-2 binds to the drug response element and transactivates the human apoA-I promoter: Role of gemfibrozil
31. Promoter elements and factors involved in hepatic transcription of the human ApoA-I gene positive and negative regulators bind to overlapping sites
32. Polymorphisms at the 5'-end of the apolipoprotein AI gene and severity of coronary artery disease
33. Protein-DNA interactions at a drug-responsive element of the human apolipoprotein A-I gene
34. Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells
35. Gene structure of human apolipoprotein A1
36. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates
37. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: Implications for adipocyte differentiation and metabolism